Detection of predictive markers for therapeutic stratification of salivary glands tumors.

Malignant tumors of the salivary glands are rare lesions and usually have poor prognosis. Surgery is currently the only treatment option, while chemotherapy is used for palliative care in progressive disease. Several molecular changes related to the etiology and progression of salivary gland tumors have been well characterized for many years. In particular, mutational status and / or aberrant expression of certain markers such as EGFR, HER2, cKIT, BRAF and AR have also been identified in several tumor tissue types of the salivary gland, and currently, new and effective drugs It represents daily use. Molecular target to treat other tumors such as breast, lung, GIST, melanoma. These expression analyzes of biomarkers associated with histomorphometric data can provide opportunities for oncologists to create appropriate patient stratification for customized therapies. This review outlines salivary gland lesions. This is best characterized by the molecular aspects focusing on markers and molecular changes that may be important for diagnosis and treatment stratification of these tumors.

Pleomorphic adenoma is the most common salivary gland tumor in the head and neck. Metastatic polymorphic adenoma is a rare clinical case. According to the World Health Organization (WHO), the characteristics of this tumor are histologically benign but distant metastasis or local metastasis is considered. These cases were associated with the parotid gland (74%), the small salivary gland (17%), and the submandibular gland (10%). Only 17% of metastatic polymorphic adenomas are associated with previous polymorphic adenomas

Malignant tumors of the salivary glands are rare lesions and usually have poor prognosis. Surgery is currently the only treatment option, while chemotherapy is used for palliative care in progressive disease. Several molecular changes related to the etiology and progression of salivary gland tumors have been well characterized for many years. In particular, mutational status and / or aberrant expression of certain markers such as EGFR, HER2, cKIT, BRAF and AR have also been identified in several tumor tissue types of the salivary gland, and currently, new and effective drugs It represents daily use. Molecular target to treat other tumors such as breast, lung, GIST, melanoma. These expression analyzes of biomarkers associated with histomorphometric data can provide opportunities for oncologists to create appropriate patient stratification for customized therapies.

Most salivary gland tumors occur in the parotid glands. Parotid gland tumor can cause facial paralysis. Partial or complete facial paralysis occurs in up to 23% of patients with malignant parotid lesions, poor prognosis 5 palpable parotid mass or swelling, or unilateral nerve palsy can not be improved , Suspected parotid tumor. Transient ischemic attack is the development of focal or nervous system dysfunction caused by acute infarction due to impaired blood supply to a particular vascular region of the central nervous system. Symptoms may last from a few minutes to several hours and are characterized by reversibility of neuropathy. It is therefore important to identify a transient ischemic attack as a warning of an imminent stroke. 6 Clinical symptoms are widespread because there is a possibility that the vascular region of the central nervous system may be affected